Cash & Equivalents
McKesson Cash & Equivalents increased by 30.2% to $3.98B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 33.3%, from $5.96B to $3.98B. Over 5 years (FY 2021 to FY 2026), Cash & Equivalents shows a downward trend with a -9.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or operational cash burn.
Detailed definition
This represents the most liquid assets held by the company, including physical currency, bank deposits, and short-term i...
Peer comparison
Peers in pharmaceutical distribution typically maintain lean cash balances due to high working capital requirements, relying on credit facilities for liquidity.
cash_and_equivalentsHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.54B | $2.53B | $3.16B | $3.94B | $2.34B | $2.96B | $2.78B | $4.68B | $2.64B | $2.52B | $1.98B | $4.59B | $2.3B | $2.51B | $1.28B | $5.96B | $2.68B | $4.11B | $3.05B | $3.98B |
| QoQ Change | — | -0.1% | +24.7% | +24.6% | -40.5% | +26.4% | -6.1% | +68.4% | -43.6% | -4.3% | -21.4% | +131.2% | -49.7% | +9.0% | -48.9% | +364.6% | -55.0% | +53.1% | -25.7% | +30.2% |
| YoY Change | — | — | — | — | -7.7% | +16.8% | -12.1% | +18.9% | +12.7% | -14.7% | -28.6% | -2.0% | -12.6% | -0.5% | -35.4% | +29.9% | +16.4% | +63.6% | +138.1% | -33.3% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is McKesson's cash & equivalents?
- McKesson (MCK) reported cash & equivalents of $3.98B in Q1 2026.
- How has McKesson's cash & equivalents changed year-over-year?
- McKesson's cash & equivalents decreased by 33.3% year-over-year, from $5.96B to $3.98B.
- What is the long-term trend for McKesson's cash & equivalents?
- Over 5 years (2021 to 2026), McKesson's cash & equivalents has grown at a -9.1% compound annual growth rate (CAGR), from $6.4B to $3.98B.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments the company has on hand.